Celebrex Growth Is "Typical" Of NSAIDs After Three Years, Pharmacia Says
Executive Summary
Pharmacia's Celebrex is showing a growth curve that is typical for products in the non-steroidal anti-inflammatory class, CEO Fred Hassan acknowledged during a July 25 analysts call.
You may also be interested in...
Medicare Rx Benefit Could Help Ignite COX-2 Market – Pharmacia’s Hassan
A Medicare drug benefit could help jump-start the stalled COX-2 inhibitor market, Pharmacia CEO Fred Hassan told analysts during the company's annual investor day in New York City Nov. 28
Medicare Rx Benefit Could Help Ignite COX-2 Market – Pharmacia’s Hassan
A Medicare drug benefit could help jump-start the stalled COX-2 inhibitor market, Pharmacia CEO Fred Hassan told analysts during the company's annual investor day in New York City Nov. 28
Pharmacia Bextra Will Test COX-2 Market; Valdecoxib Clears FDA Nov. 16
Pharmacia's Bextra (valdecoxib) launch will test the hypothesis that the recent slow-down in the growth of Celebrex reflects a traditional nonsteroidal anti-inflammatory drug product lifecycle